Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.96−0.04 (-0.80%)
Close on Nov 17, 2026Market cap $193.13MP/E –Yield –
Entrada Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Entrada Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$176.53M. For fiscal 2025 it was -$157.90M, down 435.9% from the year before. The highest annual figure on record is $47.01M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$157.90M | -435.9% |
| FY2024 | Dec 31, 2024 | $47.01M | – |
| FY2023 | Dec 31, 2023 | -$3.16M | – |
| FY2022 | Dec 31, 2022 | -$97.25M | – |
| FY2021 | Dec 31, 2021 | -$51.13M | – |
| FY2020 | Dec 31, 2020 | -$26.67M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.21M | – |
| Q3 FY2025 | Sep 30, 2025 | -$47.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.85M | -187.7% |
| Q1 FY2025 | Mar 31, 2025 | -$21.79M | -203.2% |
| Q4 FY2024 | Dec 31, 2024 | -$5.87M | -219.6% |
| Q3 FY2024 | Sep 30, 2024 | -$21.66M | -254.6% |
| Q2 FY2024 | Jun 30, 2024 | $53.42M | – |
| Q1 FY2024 | Mar 31, 2024 | $21.11M | – |
| Q4 FY2023 | Dec 31, 2023 | $4.91M | – |
| Q3 FY2023 | Sep 30, 2023 | $14.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.94M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.97M | – |
See a number that looks wrong?